Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma: a Population-based Cohort Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,677
- 试验地点
- 1
- 主要终点
- Overall survival (OS)
研究概览
简要总结
Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are:
What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients?
Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.
详细描述
Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. This cohort study aims to identify prognostic factors, construct predictive nomograms, and optimize surgical treatment for sporadic BRCC patients. The main questions it aims to answer are:
What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? In this retrospective population-based cohort study, patients diagnosed with sporadic BRCC between 2000 and 2020 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Clinical diagnosis of localized BRCC (M0) from 2000 to
- •Active follow-up.
- •Complete clinicopathological information.
排除标准
- •Diagnosed by autopsy or death certificate only.
- •Tending to suffer from hereditary RCC, including those complicating with pancreatic neuroendocrine tumor (pNET) or hemangioblastoma.
- •Unavailable key information.
结局指标
主要结局
Overall survival (OS)
时间窗: From date of diagnosis of the second primary RCC until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 20 years.
OS was calculated as the time interval from the diagnosis of the second primary RCC to death or the time to the last follow-up.
次要结局
- Cancer-specific survival (CSS)(From date of diagnosis of the second primary RCC until the date of death from the same disease or the date of last follow-up, whichever came first, assessed up to 20 years.)
研究者
GONG Kan
Chief physician
Peking University First Hospital